The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hereditary Transthyretin Amyloidosis (HATTR) Market Research Report 2025
Synopsis
Hereditary Transthyretin Amyloidosis (HATTR) is caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently result in instability of TTR and subsequent fibril formation. HATTR can be sub-classified into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The deposition of TTR amyloid fibrils in various tissues leads to ATTR, including Familial ATTR (hereditary ATTR) and non-hereditary ATTR types. Familial ATTR is a rare disorder with unequal distribution all around the world.
The global Hereditary Transthyretin Amyloidosis (HATTR) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Hereditary Transthyretin Amyloidosis (HATTR) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hereditary Transthyretin Amyloidosis (HATTR) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Hereditary Transthyretin Amyloidosis (HATTR) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Hereditary Transthyretin Amyloidosis (HATTR) include Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Prothena, Lonis Pharmaceuticals, Eidos Therapeutics and Corino Therapeutics Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Hereditary Transthyretin Amyloidosis (HATTR), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Transthyretin Amyloidosis (HATTR).
Report Scope
The Hereditary Transthyretin Amyloidosis (HATTR) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hereditary Transthyretin Amyloidosis (HATTR) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hereditary Transthyretin Amyloidosis (HATTR) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Alnylam Pharmaceuticals
Akcea Therapeutics
Prothena
Lonis Pharmaceuticals
Eidos Therapeutics
Corino Therapeutics Inc
Segment by Type
Oral
Subcutaneous Injection
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hereditary Transthyretin Amyloidosis (HATTR) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hereditary Transthyretin Amyloidosis (HATTR) is caused by the misfolding of protein monomers derived from the tetrameric protein transthyretin (TTR). Mutations in the gene for TTR frequently result in instability of TTR and subsequent fibril formation. HATTR can be sub-classified into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). The deposition of TTR amyloid fibrils in various tissues leads to ATTR, including Familial ATTR (hereditary ATTR) and non-hereditary ATTR types. Familial ATTR is a rare disorder with unequal distribution all around the world.
The global Hereditary Transthyretin Amyloidosis (HATTR) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Hereditary Transthyretin Amyloidosis (HATTR) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hereditary Transthyretin Amyloidosis (HATTR) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Hereditary Transthyretin Amyloidosis (HATTR) in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Hereditary Transthyretin Amyloidosis (HATTR) include Pfizer, Alnylam Pharmaceuticals, Akcea Therapeutics, Prothena, Lonis Pharmaceuticals, Eidos Therapeutics and Corino Therapeutics Inc, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Hereditary Transthyretin Amyloidosis (HATTR), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Transthyretin Amyloidosis (HATTR).
Report Scope
The Hereditary Transthyretin Amyloidosis (HATTR) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hereditary Transthyretin Amyloidosis (HATTR) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hereditary Transthyretin Amyloidosis (HATTR) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Alnylam Pharmaceuticals
Akcea Therapeutics
Prothena
Lonis Pharmaceuticals
Eidos Therapeutics
Corino Therapeutics Inc
Segment by Type
Oral
Subcutaneous Injection
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hereditary Transthyretin Amyloidosis (HATTR) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Subcutaneous Injection
1.2.4 Others
1.3 Market by Application
1.3.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Perspective (2019-2030)
2.2 Hereditary Transthyretin Amyloidosis (HATTR) Growth Trends by Region
2.2.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hereditary Transthyretin Amyloidosis (HATTR) Historic Market Size by Region (2019-2024)
2.2.3 Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Region (2025-2030)
2.3 Hereditary Transthyretin Amyloidosis (HATTR) Market Dynamics
2.3.1 Hereditary Transthyretin Amyloidosis (HATTR) Industry Trends
2.3.2 Hereditary Transthyretin Amyloidosis (HATTR) Market Drivers
2.3.3 Hereditary Transthyretin Amyloidosis (HATTR) Market Challenges
2.3.4 Hereditary Transthyretin Amyloidosis (HATTR) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hereditary Transthyretin Amyloidosis (HATTR) Players by Revenue
3.1.1 Global Top Hereditary Transthyretin Amyloidosis (HATTR) Players by Revenue (2019-2024)
3.1.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share by Players (2019-2024)
3.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hereditary Transthyretin Amyloidosis (HATTR) Revenue
3.4 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Concentration Ratio
3.4.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hereditary Transthyretin Amyloidosis (HATTR) Revenue in 2023
3.5 Hereditary Transthyretin Amyloidosis (HATTR) Key Players Head office and Area Served
3.6 Key Players Hereditary Transthyretin Amyloidosis (HATTR) Product Solution and Service
3.7 Date of Enter into Hereditary Transthyretin Amyloidosis (HATTR) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hereditary Transthyretin Amyloidosis (HATTR) Breakdown Data by Type
4.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Historic Market Size by Type (2019-2024)
4.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Type (2025-2030)
5 Hereditary Transthyretin Amyloidosis (HATTR) Breakdown Data by Application
5.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Historic Market Size by Application (2019-2024)
5.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2019-2030)
6.2 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024)
6.4 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2019-2030)
7.2 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024)
7.4 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2019-2030)
8.2 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region (2019-2024)
8.4 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2019-2030)
9.2 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024)
9.4 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2019-2030)
10.2 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024)
10.4 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Introduction
11.1.4 Pfizer Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Company Detail
11.2.2 Alnylam Pharmaceuticals Business Overview
11.2.3 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Introduction
11.2.4 Alnylam Pharmaceuticals Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
11.2.5 Alnylam Pharmaceuticals Recent Development
11.3 Akcea Therapeutics
11.3.1 Akcea Therapeutics Company Detail
11.3.2 Akcea Therapeutics Business Overview
11.3.3 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Introduction
11.3.4 Akcea Therapeutics Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
11.3.5 Akcea Therapeutics Recent Development
11.4 Prothena
11.4.1 Prothena Company Detail
11.4.2 Prothena Business Overview
11.4.3 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Introduction
11.4.4 Prothena Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
11.4.5 Prothena Recent Development
11.5 Lonis Pharmaceuticals
11.5.1 Lonis Pharmaceuticals Company Detail
11.5.2 Lonis Pharmaceuticals Business Overview
11.5.3 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Introduction
11.5.4 Lonis Pharmaceuticals Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
11.5.5 Lonis Pharmaceuticals Recent Development
11.6 Eidos Therapeutics
11.6.1 Eidos Therapeutics Company Detail
11.6.2 Eidos Therapeutics Business Overview
11.6.3 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Introduction
11.6.4 Eidos Therapeutics Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
11.6.5 Eidos Therapeutics Recent Development
11.7 Corino Therapeutics Inc
11.7.1 Corino Therapeutics Inc Company Detail
11.7.2 Corino Therapeutics Inc Business Overview
11.7.3 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Introduction
11.7.4 Corino Therapeutics Inc Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
11.7.5 Corino Therapeutics Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Oral
Table 3. Key Players of Subcutaneous Injection
Table 4. Key Players of Others
Table 5. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Region (2019-2024)
Table 9. Global Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Region (2025-2030)
Table 11. Hereditary Transthyretin Amyloidosis (HATTR) Market Trends
Table 12. Hereditary Transthyretin Amyloidosis (HATTR) Market Drivers
Table 13. Hereditary Transthyretin Amyloidosis (HATTR) Market Challenges
Table 14. Hereditary Transthyretin Amyloidosis (HATTR) Market Restraints
Table 15. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Players (2019-2024)
Table 17. Global Top Hereditary Transthyretin Amyloidosis (HATTR) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Transthyretin Amyloidosis (HATTR) as of 2023)
Table 18. Ranking of Global Top Hereditary Transthyretin Amyloidosis (HATTR) Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Hereditary Transthyretin Amyloidosis (HATTR) Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Hereditary Transthyretin Amyloidosis (HATTR) Product Solution and Service
Table 22. Date of Enter into Hereditary Transthyretin Amyloidosis (HATTR) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share by Type (2019-2024)
Table 26. Global Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share by Type (2025-2030)
Table 28. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share by Application (2019-2024)
Table 30. Global Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share by Application (2025-2030)
Table 32. North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2025-2030) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Product
Table 50. Pfizer Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Alnylam Pharmaceuticals Company Detail
Table 53. Alnylam Pharmaceuticals Business Overview
Table 54. Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Product
Table 55. Alnylam Pharmaceuticals Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024) & (US$ Million)
Table 56. Alnylam Pharmaceuticals Recent Development
Table 57. Akcea Therapeutics Company Detail
Table 58. Akcea Therapeutics Business Overview
Table 59. Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product
Table 60. Akcea Therapeutics Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024) & (US$ Million)
Table 61. Akcea Therapeutics Recent Development
Table 62. Prothena Company Detail
Table 63. Prothena Business Overview
Table 64. Prothena Hereditary Transthyretin Amyloidosis (HATTR) Product
Table 65. Prothena Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024) & (US$ Million)
Table 66. Prothena Recent Development
Table 67. Lonis Pharmaceuticals Company Detail
Table 68. Lonis Pharmaceuticals Business Overview
Table 69. Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Product
Table 70. Lonis Pharmaceuticals Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024) & (US$ Million)
Table 71. Lonis Pharmaceuticals Recent Development
Table 72. Eidos Therapeutics Company Detail
Table 73. Eidos Therapeutics Business Overview
Table 74. Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product
Table 75. Eidos Therapeutics Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024) & (US$ Million)
Table 76. Eidos Therapeutics Recent Development
Table 77. Corino Therapeutics Inc Company Detail
Table 78. Corino Therapeutics Inc Business Overview
Table 79. Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Product
Table 80. Corino Therapeutics Inc Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024) & (US$ Million)
Table 81. Corino Therapeutics Inc Recent Development
Table 82. Research Programs/Design for This Report
Table 83. Key Data Information from Secondary Sources
Table 84. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Type: 2023 VS 2030
Figure 3. Oral Features
Figure 4. Subcutaneous Injection Features
Figure 5. Others Features
Figure 6. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Application: 2023 VS 2030
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Hereditary Transthyretin Amyloidosis (HATTR) Report Years Considered
Figure 12. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Region: 2023 VS 2030
Figure 15. Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Players in 2023
Figure 16. Global Top Hereditary Transthyretin Amyloidosis (HATTR) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Transthyretin Amyloidosis (HATTR) as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Hereditary Transthyretin Amyloidosis (HATTR) Revenue in 2023
Figure 18. North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Country (2019-2030)
Figure 20. United States Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Country (2019-2030)
Figure 24. Germany Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Region (2019-2030)
Figure 32. China Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Country (2019-2030)
Figure 40. Mexico Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Country (2019-2030)
Figure 44. Turkey Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Pfizer Revenue Growth Rate in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
Figure 47. Alnylam Pharmaceuticals Revenue Growth Rate in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
Figure 48. Akcea Therapeutics Revenue Growth Rate in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
Figure 49. Prothena Revenue Growth Rate in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
Figure 50. Lonis Pharmaceuticals Revenue Growth Rate in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
Figure 51. Eidos Therapeutics Revenue Growth Rate in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
Figure 52. Corino Therapeutics Inc Revenue Growth Rate in Hereditary Transthyretin Amyloidosis (HATTR) Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
